Core Insights - The global chronic ocular pain market is valued at US$ 7.2 billion in 2023 and is projected to reach US$ 12.44 billion by 2032, with a CAGR of 6.6% during the forecast period from 2024 to 2032 [8] Company Developments - Channel Therapeutics Corporation has achieved predefined endpoints in two pre-clinical animal models for its eye drop formulation CT2000, targeting both acute ocular pain and chronic ocular surface pain associated with dry eye disease [1][2] - The results from animal efficacy studies support the potential of CT2000 in treating post-surgical pain and chronic eye pain, reinforcing the genetic validation of NaV1.7 as a target for pain management [2] Trial Results - In the first trial, CT2000 significantly reduced the number of paw wipes in rabbits treated with capsaicin, indicating a reduction in acute ocular pain within 15 minutes of administration [3] - The second trial demonstrated that CT2000 reduced paw wipes in mice with induced dry eye disease, showing cumulative efficacy over time with repeated dosing [6] Market Opportunity - The company aims to target the existing chronic eye pain market, valued at US$ 7.2 billion, and the acute eye pain market, valued at US$ 404 million, with its CT2000 formulation [8]

under The Securities Act of 1933 CHROMOCELL THERAPEUTICS CORPORATION (Exact name of registrant as specified in its charter) FORM S-1 REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on July 29, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State or other jurisdiction of incorporation or organization) Delaware 2836 86-3335449 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 4400 R ...